BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $13.16 million. The enterprise value is $13.62 million.
Important Dates
The next estimated earnings date is Tuesday, March 25, 2025, before market open.
| Earnings Date | Mar 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 1.20 billion shares outstanding. The number of shares has increased by 23.34% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.20B |
| Shares Change (YoY) | +23.34% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.13B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 3.48.
| Current Ratio | 1.52 |
| Quick Ratio | 1.33 |
| Debt / Equity | 3.48 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.56 |
Financial Efficiency
Return on equity (ROE) is -184.09% and return on invested capital (ROIC) is -53.91%.
| Return on Equity (ROE) | -184.09% |
| Return on Assets (ROA) | -32.96% |
| Return on Invested Capital (ROIC) | -53.91% |
| Return on Capital Employed (ROCE) | -100.23% |
| Revenue Per Employee | $278,367 |
| Profits Per Employee | -$252,127 |
| Employee Count | 79 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.37% in the last 52 weeks. The beta is 0.87, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -92.37% |
| 50-Day Moving Average | 7.99 |
| 200-Day Moving Average | 20.60 |
| Relative Strength Index (RSI) | 29.63 |
| Average Volume (20 Days) | 438,744 |
Short Selling Information
| Short Interest | 1.26M |
| Short Previous Month | 822,212 |
| Short % of Shares Out | 1.33% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.39 |
Income Statement
In the last 12 months, BioLineRx had revenue of $21.99 million and -$19.92 million in losses. Loss per share was -$0.02.
| Revenue | 21.99M |
| Gross Profit | 15.13M |
| Operating Income | -27.85M |
| Pretax Income | -49.15M |
| Net Income | -19.92M |
| EBITDA | -25.49M |
| EBIT | -27.85M |
| Loss Per Share | -$0.02 |
Full Income StatementBalance Sheet
The company has $29.17 million in cash and $29.61 million in debt, giving a net cash position of -$441,000 or -$0.00 per share.
| Cash & Cash Equivalents | 29.17M |
| Total Debt | 29.61M |
| Net Cash | -441,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 8.51M |
| Book Value Per Share | 0.01 |
| Working Capital | 12.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.27 million and capital expenditures -$75,000, giving a free cash flow of -$30.35 million.
| Operating Cash Flow | -30.27M |
| Capital Expenditures | -75,000 |
| Free Cash Flow | -30.35M |
| FCF Per Share | -$0.03 |
Full Cash Flow StatementMargins
Gross margin is 68.78%, with operating and profit margins of -126.62% and -90.57%.
| Gross Margin | 68.78% |
| Operating Margin | -126.62% |
| Pretax Margin | -90.57% |
| Profit Margin | -90.57% |
| EBITDA Margin | -115.92% |
| EBIT Margin | -126.62% |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.34% |
| Shareholder Yield | -23.34% |
| Earnings Yield | -151.32% |
| FCF Yield | -230.55% |
Analyst Forecast
The average price target for BioLineRx is $5.50, which is 52.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.50 |
| Price Target Difference | 52.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
BioLineRx has an Altman Z-Score of -10.48. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.48 |
| Piotroski F-Score | n/a |